Abstract

Few data are available on the incidence of deep vein thrombosis (DVT) in critically ill COVID-19 with thrombosis prophylaxis. This study retrospectively included 88 patients in the ICU with critically ill COVID-19 at Jinyintan Hospital in Wuhan, China. All patients underwent compression ultrasonography for identifying DVT. Firth logistic regression was used to examine the association of DVT with sex, age, hypoalbuminemia, D-dimer, and SOFA score. The median (interquartile range [IQR]) age and SOFA score of 88 patients were 63 (55–71) years old and 5 (4–6), respectively. Despite all patients receiving guideline-recommended low-molecular-weight heparin (LMWH) thromboprophylaxis, the incidence of DVT was 46% (95% CI 35–56%). Proximal DVT was recognized in 9% (95% CI 3–15%) of the patients, while 46% (95% CI 35–56%) of patients had distal DVT. All of the proximal DVT combined with distal DVT. Risk factors of DVT extension occurred in all distal DVT patients. As Padua score ≥ 4 or IMPROVE score ≥ 2, 53% and 46% of patients had DVT, respectively. Mortality was higher in patients with acute DVT (30%) compared with non-DVT (17%), but did not reach statistical significance. Hypoalbuminemia (odds ratio [OR], 0.17; 95% CI 0.06–0.05, P = 0.001), higher SOFA score (OR per IQR, 2.07; 95% CI 1.38–3.39, P = 0.001), and elevated D-dimer (OR per IQR, 1.04; 95% CI 1.03–1.84, P = 0.029) were significant DVT risk factors in multivariable analyses. High incidence of DVT was identified in patients with critically ill COVID-19, despite the use of guideline-recommended pharmacologic thromboprophylaxis. The presence of hypoalbuminemia, higher SOFA score, and elevated D-dimer were significantly independent risk factors of DVT. More effective VTE prevention and management strategies may need to be addressed.

Highlights

  • The global pandemic of novel coronavirus disease 2019 (COVID-19) is still under rapid progression worldwide and causes thousands of deaths daily [1], since its first outbreak in Wuhan, China since December 2019 [2]

  • There were 260 critically ill patients who received at least standard doses of pharmacologic thromboprophylaxis for more than 1 week after intensive care unit (ICU) admission according to their venous thromboembolism risk assessment and bleeding risk assessment [3, 16]

  • We investigated the deep vein thrombosis (DVT) incidence, outcomes, and risk factors in patients admitted to the ICU with critically ill COVID-19 after low-molecular-weight heparin (LMWH) thromboprophylaxis

Read more

Summary

Introduction

The global pandemic of novel coronavirus disease 2019 (COVID-19) is still under rapid progression worldwide and causes thousands of deaths daily [1], since its first outbreak in Wuhan, China since December 2019 [2]. Ill COVID-19, especially complicated by bedridden, obesity. There are few studies investigating DVT incidence and risk factors in patients with critically ill COVID-19 with guideline-recommended LMWH prophylaxis. Some researchers found the incidence of PE in ICU were 4–30% with different prophylaxis strategies [8,9,10,11,12,13]. More data are needed to make new strategies of DVT prophylaxis in critically ill COVID-19. Identification of DVT incidence and risk factors in critically ill COVID-19, especially in the use of guideline-recommended pharmacologic thromboprophylaxis, remains important. Our study’s purpose was to identify the incidence of DVT and the independent risk factors of DVT in critically ill COVID-19 patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call